Combination Therapy of Imatinib Mesylate and Interferon-α Demonstrates Minimal Activity and Significant Toxicity in Metastatic Renal Cell Carcinoma: Results of a Single-Institution Phase II Trial
- Resource Type
- Article
- Source
- In
Clinical Genitourinary Cancer 2006 4(4):275-280 - Subject
- Language
- ISSN
- 1558-7673